Oral News and Research

RSS

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

The link between Hormone Replacement Therapy and reduced risk of distal large bowel cancer in women; a promising combination antibiotic therapy for ulcerative colitis patients; and the high-rate of alcoholic liver disease mortality, are among the scientific findings featured in the August issue of The American Journal of Gastroenterology.

6 Aug 2010

New research on use of medicine, diet to prevent UV-induced skin cancer

In most cases, non-melanoma skin cancers are caused by overexposure to ultraviolet radiation - the invisible rays from the sun that can burn the skin. To reduce the risk of skin cancer, dermatologists encourage the public to Be Sun Smart, including limiting sun exposure and using broad-spectrum sunscreens.

6 Aug 2010

Incyte second-quarter total revenues increase to $49.8 million

Incyte Corporation today reported second quarter 2010 financial results and described progress for several of its clinical programs.

5 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Watson Pharmaceuticals second-quarter 2010 net revenue increases 29%

Watson Pharmaceuticals, Inc. today reported net revenue grew 29 percent for the second quarter ended June 30, 2010 to $875.3 million, compared to $677.8 million in the second quarter 2009. On an adjusted cash basis, net income increased 22 percent to $102.8 million or $0.83 per share, compared to $84.2 million or $0.73 per share in the second quarter 2009. GAAP earnings for the second quarter 2010 were $0.57 per share, compared to $0.46 per share in the prior year period.

5 Aug 2010

Jagged2 gene essential for healthy development of teeth: Study

No healthy teeth without this gene: if during tooth formation (odontogenesis) the so-called Jagged2 gene is inactivated, and hence the Notch signalling pathway interrupted, tooth crowns will be malformed and enamel will be lacking. As this signalling pathway is involved in the formation of all tissues and organs, the new insights from the University of Zurich research team have wider implications.

5 Aug 2010

Vanda second-quarter 2010 revenues decrease by $4.1M

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the second quarter and six months ended June 30, 2010.

5 Aug 2010

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Merck reported that two pivotal Phase III registration studies for boceprevir, its investigational oral hepatitis C protease inhibitor, have been completed and met the primary endpoints: in both studies in patients with chronic hepatitis C virus (HCV) genotype 1 infection, the addition of boceprevir to treatment with PEGINTRON® and REBETOL® significantly increased the number of patients who achieved sustained virologic response, compared to control groups that received Peg/riba plus placebo.

5 Aug 2010

Western Dental Services opens new office in Porterville to provide dentistry services

Western Dental Services, Inc., California's neighborhood dentist and one of the nation's leading dental health maintenance organizations, is opening a combined family dentistry, specialty, cosmetic, and orthodontics office in Porterville, Calif., on August 13, 2010. The office will provide a full range of family dentistry services, specialty care, and cosmetic dentistry, including white fillings, veneers, crowns, dental implants, ZOOM! whitening, oral surgery, periodontics, pedodontics, and complete orthodontic services by certified specialists and experienced providers.

5 Aug 2010

FDA issues Lux Biosciences Complete Response letter for Luveniq NDA

Lux Biosciences, Inc. today announced that the U.S. Food and Drug Administration's Center of Drug Evaluation and Research has issued a Complete Response letter regarding the New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis.

5 Aug 2010

Scientists develop laser probe for early detection of oral cancer

UC Davis researchers have developed a laser probe for the early detection of oral cancer. A trial with human subjects shows that the device could also be used during surgery to locate the edges of a tumor.

5 Aug 2010

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical Companies, Inc. today reported results for the second quarter ended June 30, 2010.

4 Aug 2010

Infinity reports $18.4 million total revenue for second-quarter 2010

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today detailed recent developments in its product development portfolio and announced second quarter 2010 financial results.

4 Aug 2010

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Matrixx Initiatives, Inc., an over-the-counter healthcare company that develops and markets Zicam® products, today announced financial results for its fiscal first quarter ended June 30, 2010.

4 Aug 2010

Study shows oral contraceptive use increases risk of breast cancer in African American women

Investigators from the Slone Epidemiology Center at Boston University School of Medicine have reported that African American women who use oral contraceptives have a greater likelihood of developing breast cancer than nonusers. The study results, recently published on-line in Cancer Epidemiology Biomarkers and Prevention, were based on data from the Black Women's Health Study, a large follow-up study of 59,000 African American women from across the U.S. conducted by investigators at the Slone Epidemiology Center since 1995.

4 Aug 2010

Periodontal disease may increase risk of cognitive dysfunction: Researchers

NYU dental researchers have found the first long-term evidence that periodontal (gum) disease may increase the risk of cognitive dysfunction associated with Alzheimer's disease in healthy individuals as well as in those who already are cognitively impaired.

4 Aug 2010

Judge gives the go-ahead to Virginia's health overhaul challenge

In a ruling issued Monday, U.S. District Judge Henry Hudson refused to dismiss the lawsuit filed by Virginia challenging a key aspect of the health care overhaul. The next round of arguments in this case is scheduled for October.

4 Aug 2010

Smokefree enters joint venture with Colorado to market smoke-free pharmacological products

Smokefree Innotec, Inc. Thomas Schroepfer, CEO, announced today that the Company has executed a Joint venture agreement with a Colorado research and development corporation focusing on natural holistic and herbal medical compounds, operating out of laboratory facilities located in Colorado Springs. The business objective is to jointly develop and market several smoke-free high tech natural and herbal pharmacological products, initially based upon an oral delivery system utilizing the innovative technology developed for the "REAL Smokefree Cigarette". Under this joint venture Smokefree Innotec, Inc. will provide its smoke-free products and devices, and its venture partner will provide all the medical extract formulations to the Company.

4 Aug 2010

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Titan Pharmaceuticals, Inc. today announced that patient enrollment is more than 60% complete in the confirmatory Phase 3 clinical study of Probuphine for the treatment of opioid addiction, and the study is expected to complete enrollment by early fourth quarter of this year, which is almost three months ahead of schedule.

3 Aug 2010

Oral News and Research

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Scientific findings reveal combination antibiotic therapy effective for ulcerative colitis

New research on use of medicine, diet to prevent UV-induced skin cancer

Incyte second-quarter total revenues increase to $49.8 million

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Watson Pharmaceuticals second-quarter 2010 net revenue increases 29%

Jagged2 gene essential for healthy development of teeth: Study

Vanda second-quarter 2010 revenues decrease by $4.1M

Merck's two pivotal boceprevir Phase III registration studies for chronic HCV meet primary endpoint

Western Dental Services opens new office in Porterville to provide dentistry services

FDA issues Lux Biosciences Complete Response letter for Luveniq NDA

Scientists develop laser probe for early detection of oral cancer

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Infinity reports $18.4 million total revenue for second-quarter 2010

Matrixx Initiatives first-quarter net loss reduces to $2.4 million

Study shows oral contraceptive use increases risk of breast cancer in African American women

Periodontal disease may increase risk of cognitive dysfunction: Researchers

Judge gives the go-ahead to Virginia's health overhaul challenge

Smokefree enters joint venture with Colorado to market smoke-free pharmacological products

Titan completes 60% enrollment in confirmatory Phase 3 clinical study of Probuphine for opioid addiction

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News